Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
NCT05052853Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Nov 2021
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Scale of Prodromal Symptoms Total Score at week 12. Started Nov 2021; status: recruiting.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05052853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052853.